2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimens
2017
Cytologic predictors of malignancy in bile duct brushings: a multi-reviewer analysis of 60 cases
Avadhani V, Hacihasanoglu E, Memis B, Pehlivanoglu B, Hanley K, Krishnamurti U, Krasinskas A, Osunkoya A, Daniels L, Freedman A, Goodman M, Adsay V, Reid M. Cytologic predictors of malignancy in bile duct brushings: a multi-reviewer analysis of 60 cases. Modern Pathology 2017, 30: 1273-1286. PMID: 28664934, DOI: 10.1038/modpathol.2017.51.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Krishnamurti U, Wetherilt C, Yang J, Peng L, Li X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology 2017, 64: 7-12. PMID: 28153508, DOI: 10.1016/j.humpath.2017.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansLogistic ModelsLymphatic MetastasisLymphocytes, Tumor-InfiltratingMastectomyMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPredictive Value of TestsProportional Hazards ModelsReceptors, EstrogenRisk FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesDisease-free survivalBetter overall survivalLymph node statusOverall survivalBreast cancerNeoadjuvant treatmentLymphovascular invasionEstrogen receptor-positive breast cancerReceptor-positive breast cancerOncotype DX recurrence scoreOncotype DX scorePossible prognostic valueDX recurrence scoreNottingham histologic gradeNeoadjuvant settingTILs correlateNegative associationNode statusPrognostic valueRecurrence scoreHistologic gradePrognostic parametersPathological response
2015
GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology
Deftereos G, Ramirez A, Silverman J, Krishnamurti U. GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology. The American Journal Of Surgical Pathology 2015, 39: 1282-1289. PMID: 26274030, DOI: 10.1097/pas.0000000000000505.Peer-Reviewed Original ResearchConceptsTriple-negative breast carcinomaGCDFP-15Breast carcinomaCytology casesGynecologic malignanciesER expressionHistologic subtypeExpression correlatesMetastatic gynecologic malignanciesMetastatic breast carcinomaNegative breast carcinomaPrimary breast carcinomaStaining scoresNegative carcinomasOvarian carcinomaImmunohistochemistry expressionHistology casesMammaglobinCarcinomaIntensity scoresGATA3 expressionSubtypesGATA3Cancer cellsBreast
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapy
2013
The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions
Deftereos G, Finkelstein S, Jackson S, Ellsworth E, Krishnamurti U, Liu Y, Silverman J, Binkert C, Ujevich B, Mohanty A. The value of mutational profiling of the cytocentrifugation supernatant fluid from fine-needle aspiration of pancreatic solid mass lesions. Modern Pathology 2013, 27: 594-601. PMID: 24051700, DOI: 10.1038/modpathol.2013.147.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorBiopsy, Fine-NeedleCentrifugationDNA Mutational AnalysisDNA, NeoplasmGenetic Predisposition to DiseaseHumansLoss of HeterozygosityMicrodissectionMutationPancreatic NeoplasmsPolymerase Chain ReactionPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsFine-needle aspirationPancreatic solid massesDiagnostic yieldSupernatant fluidTumor DNASolid massHigh clinical suspicionDetectable mutationsSolid mass lesionQuantitative PCRClinical suspicionAtypical cellsDefinitive diagnosisMass lesionCytology smearsFluid specimensFNA smearsMolecular analysisAdjunct methodAdequate DNAMutational profilingCell blocksCytocentrifugation supernatant fluidSmearsBroad panel
2011
Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research
Miguel R, Chivukula M, Krishnamurti U, Amortegui A, Kant J, Sweet R, Wiesenfeld H, Phillips J, Cherpes T. Limitations of the criteria used to diagnose histologic endometritis in epidemiologic pelvic inflammatory disease research. Pathology - Research And Practice 2011, 207: 680-685. PMID: 21996319, PMCID: PMC3215901, DOI: 10.1016/j.prp.2011.08.007.Peer-Reviewed Original ResearchConceptsHistologic endometritisPlasma cellsInflammatory disease researchLower riskEndometrial leukocyte subpopulationsEndometrial biopsy specimensAdditional immunohistochemical analysisDisease researchEndometrial neutrophilsChronic endometritisEndometrial biopsyInflammatory infiltrateConventional criteriaBiopsy specimensInflammatory processLeukocyte subpopulationsImmunohistochemical analysisEndometritisCytometric analysisWomenPID developmentCellsRiskInfiltratesBiopsy